cbor-x 1.2.1 → 1.3.2
This diff represents the content of publicly available package versions that have been released to one of the supported registries. The information contained in this diff is provided for informational purposes only and reflects changes between package versions as they appear in their respective public registries.
- package/decode.d.ts +1 -0
- package/dist/node.cjs +10 -8
- package/dist/test.js +4 -580
- package/index.d.ts +3 -2
- package/node-index.js +10 -8
- package/package.json +2 -5
package/decode.d.ts
CHANGED
|
@@ -39,6 +39,7 @@ export class Decoder {
|
|
|
39
39
|
export function decode(messagePack: Buffer | Uint8Array): any
|
|
40
40
|
export function decodeMultiple(messagePack: Buffer | Uint8Array, forEach?: (value: any) => any): [] | void
|
|
41
41
|
export function addExtension(extension: Extension): void
|
|
42
|
+
export function clearSource(): void
|
|
42
43
|
export function roundFloat32(float32Number: number): number
|
|
43
44
|
export let isNativeAccelerationEnabled: boolean
|
|
44
45
|
|
package/dist/node.cjs
CHANGED
|
@@ -2250,17 +2250,19 @@ function decodeIter (bufferIterator, options = {}) {
|
|
|
2250
2250
|
const useRecords = false;
|
|
2251
2251
|
const mapsAsObjects = true;
|
|
2252
2252
|
|
|
2253
|
-
const
|
|
2254
|
-
if (extractor)
|
|
2255
|
-
setExtractor(extractor.extractStrings);
|
|
2253
|
+
const nativeAccelerationDisabled = process.env.CBOR_NATIVE_ACCELERATION_DISABLED !== undefined && process.env.CBOR_NATIVE_ACCELERATION_DISABLED.toLowerCase() === 'true';
|
|
2256
2254
|
|
|
2257
|
-
|
|
2255
|
+
if (!nativeAccelerationDisabled) {
|
|
2256
|
+
let extractor;
|
|
2258
2257
|
try {
|
|
2259
|
-
|
|
2260
|
-
|
|
2258
|
+
if (typeof require == 'function')
|
|
2259
|
+
extractor = require('cbor-extract');
|
|
2260
|
+
else
|
|
2261
|
+
extractor = module$1.createRequire((typeof document === 'undefined' ? new (require('u' + 'rl').URL)('file:' + __filename).href : (document.currentScript && document.currentScript.src || new URL('node.cjs', document.baseURI).href)))('cbor-extract');
|
|
2262
|
+
if (extractor)
|
|
2263
|
+
setExtractor(extractor.extractStrings);
|
|
2261
2264
|
} catch (error) {
|
|
2262
|
-
|
|
2263
|
-
console.warn('For browser usage, directly use cbor-x/decode or cbor-x/encode modules. ' + error.message.split('\n')[0]);
|
|
2265
|
+
// native module is optional
|
|
2264
2266
|
}
|
|
2265
2267
|
}
|
|
2266
2268
|
|
package/dist/test.js
CHANGED
|
@@ -1,586 +1,10 @@
|
|
|
1
|
-
(function (CBOR, chai) {
|
|
1
|
+
(function (CBOR, chai, fs) {
|
|
2
2
|
'use strict';
|
|
3
3
|
|
|
4
4
|
chai = chai && Object.prototype.hasOwnProperty.call(chai, 'default') ? chai['default'] : chai;
|
|
5
5
|
|
|
6
|
-
|
|
7
|
-
|
|
8
|
-
"Randomized Controlled Trial"
|
|
9
|
-
],
|
|
10
|
-
Types: [
|
|
11
|
-
],
|
|
12
|
-
BriefSummary: "To determine the efficacy, long-term safety, and tolerability of alirocumab 300 mg every 4\n weeks (Q4W), in comparison with placebo, as well as its potential as a starting regimen. The\n dose regimen of 75 mg every 2 weeks (Q2W), as used in other studies, was added as a\n calibrator.",
|
|
13
|
-
Abstract: "To determine the efficacy, long-term safety, and tolerability of alirocumab 300 mg every 4\n weeks (Q4W), in comparison with placebo, as well as its potential as a starting regimen. The\n dose regimen of 75 mg every 2 weeks (Q2W), as used in other studies, was added as a\n calibrator.",
|
|
14
|
-
Acronym: null,
|
|
15
|
-
ArticleId: "Qy3gwKWSoaWRmbmFEQA",
|
|
16
|
-
Authors: null,
|
|
17
|
-
CochraneID: null,
|
|
18
|
-
Confidential: false,
|
|
19
|
-
CorporateAuthor: null,
|
|
20
|
-
Country: "Bulgaria, Canada, Hungary, Israel, Norway, Slovakia, United Kingdom, United States",
|
|
21
|
-
CustomData: null,
|
|
22
|
-
DatabaseType: "ClinicalTrials.gov",
|
|
23
|
-
DOI: null,
|
|
24
|
-
EmbaseAccessionNumber: null,
|
|
25
|
-
Emtree: null,
|
|
26
|
-
ErrataText: null,
|
|
27
|
-
FullTextURL: null,
|
|
28
|
-
Institution: null,
|
|
29
|
-
ISSN: null,
|
|
30
|
-
Issue: null,
|
|
31
|
-
JournalTitle: null,
|
|
32
|
-
MedlineID: null,
|
|
33
|
-
MeSH: "Hypercholesterolemia|Antibodies, Monoclonal",
|
|
34
|
-
Pages: null,
|
|
35
|
-
ParentChildStatus: null,
|
|
36
|
-
ParentID: null,
|
|
37
|
-
PublicationDate: "March 21, 2017",
|
|
38
|
-
PublicationYear: 2017,
|
|
39
|
-
PubType: null,
|
|
40
|
-
ReferenceStudy: null,
|
|
41
|
-
SecondarySourceID: null,
|
|
42
|
-
Source: "Regeneron Pharmaceuticals",
|
|
43
|
-
SourceReferenceId: "NCT01926782",
|
|
44
|
-
TaStudyDesign: "Randomized",
|
|
45
|
-
Title: "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia",
|
|
46
|
-
TrialOutcome: null,
|
|
47
|
-
Volume: null,
|
|
48
|
-
Id: 179246831,
|
|
49
|
-
Created: "2020-04-10T14:48:20.4384957Z",
|
|
50
|
-
VersionNo: 2,
|
|
51
|
-
ExtractData: null,
|
|
52
|
-
Digitized: true,
|
|
53
|
-
IsRapidExtract: false,
|
|
54
|
-
IsUploaded: false
|
|
55
|
-
};
|
|
56
|
-
var design = "Randomized Controlled Trial";
|
|
57
|
-
var conditions = [
|
|
58
|
-
{
|
|
59
|
-
label: "Cholesterol Total Increased",
|
|
60
|
-
id: "SUE_c"
|
|
61
|
-
}
|
|
62
|
-
];
|
|
63
|
-
var phase = 3;
|
|
64
|
-
var name = "NCT01926782";
|
|
65
|
-
var trialIds = [
|
|
66
|
-
"NCT01926782"
|
|
67
|
-
];
|
|
68
|
-
var acronyms = [
|
|
69
|
-
];
|
|
70
|
-
var outcomeCount = 156;
|
|
71
|
-
var id = 179246831;
|
|
72
|
-
var groups = [
|
|
73
|
-
{
|
|
74
|
-
Id: "4r",
|
|
75
|
-
RefId: "B5|O2~Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin",
|
|
76
|
-
OriginalName: "Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin",
|
|
77
|
-
N: 37,
|
|
78
|
-
age: 59.3,
|
|
79
|
-
ageSD: 11.3,
|
|
80
|
-
male: 37.83783783783784,
|
|
81
|
-
Interventions: [
|
|
82
|
-
{
|
|
83
|
-
termIds: [
|
|
84
|
-
[
|
|
85
|
-
"SUBYEL",
|
|
86
|
-
"SUB_Oc"
|
|
87
|
-
],
|
|
88
|
-
[
|
|
89
|
-
"SUNUVb"
|
|
90
|
-
]
|
|
91
|
-
]
|
|
92
|
-
}
|
|
93
|
-
],
|
|
94
|
-
analyzeAs: "Alirocumab",
|
|
95
|
-
analyzableScore: 1.0717734625362931,
|
|
96
|
-
matchingScore: 0
|
|
97
|
-
},
|
|
98
|
-
{
|
|
99
|
-
Id: "zB",
|
|
100
|
-
RefId: "B6|O3~Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin",
|
|
101
|
-
OriginalName: "Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin",
|
|
102
|
-
N: 146,
|
|
103
|
-
age: 59.2,
|
|
104
|
-
ageSD: 10.8,
|
|
105
|
-
male: 45.205479452054796,
|
|
106
|
-
Interventions: [
|
|
107
|
-
{
|
|
108
|
-
termIds: [
|
|
109
|
-
[
|
|
110
|
-
"SUBYEL",
|
|
111
|
-
"SUB_Oc"
|
|
112
|
-
]
|
|
113
|
-
]
|
|
114
|
-
}
|
|
115
|
-
],
|
|
116
|
-
analyzeAs: "Statins",
|
|
117
|
-
analyzableScore: 1.0717734625362931,
|
|
118
|
-
matchingScore: 0
|
|
119
|
-
},
|
|
120
|
-
{
|
|
121
|
-
Id: "3!",
|
|
122
|
-
RefId: "B4|O1~Placebo Q2W Without Concomitant Statin",
|
|
123
|
-
OriginalName: "Placebo Q2W Without Concomitant Statin",
|
|
124
|
-
N: 73,
|
|
125
|
-
age: 59.4,
|
|
126
|
-
ageSD: 10.2,
|
|
127
|
-
male: 54.794520547945204,
|
|
128
|
-
Interventions: [
|
|
129
|
-
{
|
|
130
|
-
termIds: [
|
|
131
|
-
[
|
|
132
|
-
"SUGeLS"
|
|
133
|
-
],
|
|
134
|
-
[
|
|
135
|
-
"SUBYEL",
|
|
136
|
-
"SUB_Oc"
|
|
137
|
-
]
|
|
138
|
-
]
|
|
139
|
-
}
|
|
140
|
-
],
|
|
141
|
-
analyzeAs: "Control",
|
|
142
|
-
analyzableScore: 1.2020833333333334,
|
|
143
|
-
matchingScore: 0
|
|
144
|
-
},
|
|
145
|
-
{
|
|
146
|
-
Id: "tv",
|
|
147
|
-
RefId: "E3",
|
|
148
|
-
OriginalName: "Alirocumab 300 mg Q4W/Up 150 mg Q2W",
|
|
149
|
-
Interventions: [
|
|
150
|
-
{
|
|
151
|
-
termIds: [
|
|
152
|
-
[
|
|
153
|
-
"SUCO54",
|
|
154
|
-
"SUNUVb"
|
|
155
|
-
]
|
|
156
|
-
]
|
|
157
|
-
}
|
|
158
|
-
]
|
|
159
|
-
},
|
|
160
|
-
{
|
|
161
|
-
Id: "jt",
|
|
162
|
-
RefId: "B3|O3~Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin",
|
|
163
|
-
OriginalName: "Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin",
|
|
164
|
-
N: 312,
|
|
165
|
-
age: 61.6,
|
|
166
|
-
ageSD: 10,
|
|
167
|
-
male: 60.8974358974359,
|
|
168
|
-
Interventions: [
|
|
169
|
-
{
|
|
170
|
-
termIds: [
|
|
171
|
-
[
|
|
172
|
-
"SUBYEL",
|
|
173
|
-
"SUB_Oc"
|
|
174
|
-
]
|
|
175
|
-
]
|
|
176
|
-
}
|
|
177
|
-
]
|
|
178
|
-
},
|
|
179
|
-
{
|
|
180
|
-
Id: "5!",
|
|
181
|
-
RefId: "E2",
|
|
182
|
-
OriginalName: "Alirocumab 75 mg Q2W/Up 150 mg Q2W",
|
|
183
|
-
Interventions: [
|
|
184
|
-
{
|
|
185
|
-
termIds: [
|
|
186
|
-
[
|
|
187
|
-
"SUNUVb"
|
|
188
|
-
]
|
|
189
|
-
]
|
|
190
|
-
}
|
|
191
|
-
]
|
|
192
|
-
},
|
|
193
|
-
{
|
|
194
|
-
Id: "4E",
|
|
195
|
-
RefId: "B2|O2~Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin",
|
|
196
|
-
OriginalName: "Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin",
|
|
197
|
-
N: 78,
|
|
198
|
-
age: 60.7,
|
|
199
|
-
ageSD: 9.1,
|
|
200
|
-
male: 65.38461538461539,
|
|
201
|
-
Interventions: [
|
|
202
|
-
{
|
|
203
|
-
termIds: [
|
|
204
|
-
[
|
|
205
|
-
"SUBYEL",
|
|
206
|
-
"SUB_Oc"
|
|
207
|
-
],
|
|
208
|
-
[
|
|
209
|
-
"SUNUVb"
|
|
210
|
-
]
|
|
211
|
-
]
|
|
212
|
-
}
|
|
213
|
-
]
|
|
214
|
-
},
|
|
215
|
-
{
|
|
216
|
-
Id: "i4",
|
|
217
|
-
Interventions: [
|
|
218
|
-
{
|
|
219
|
-
Id: "Ya",
|
|
220
|
-
Name: 178613599,
|
|
221
|
-
Treatments: [
|
|
222
|
-
{
|
|
223
|
-
Id: "((",
|
|
224
|
-
Phase: "k)"
|
|
225
|
-
}
|
|
226
|
-
],
|
|
227
|
-
Type: "Drug",
|
|
228
|
-
termIds: [
|
|
229
|
-
[
|
|
230
|
-
"SUGeLS"
|
|
231
|
-
],
|
|
232
|
-
[
|
|
233
|
-
"SUNUVb"
|
|
234
|
-
]
|
|
235
|
-
],
|
|
236
|
-
terms: [
|
|
237
|
-
[
|
|
238
|
-
"Placebo"
|
|
239
|
-
],
|
|
240
|
-
[
|
|
241
|
-
"Alirocumab"
|
|
242
|
-
]
|
|
243
|
-
]
|
|
244
|
-
},
|
|
245
|
-
{
|
|
246
|
-
Id: "o)",
|
|
247
|
-
Name: 2159990,
|
|
248
|
-
Treatments: [
|
|
249
|
-
{
|
|
250
|
-
Id: "1$",
|
|
251
|
-
Phase: "k)"
|
|
252
|
-
}
|
|
253
|
-
],
|
|
254
|
-
Type: "Drug",
|
|
255
|
-
termIds: [
|
|
256
|
-
[
|
|
257
|
-
"SUBYEL"
|
|
258
|
-
]
|
|
259
|
-
],
|
|
260
|
-
terms: [
|
|
261
|
-
[
|
|
262
|
-
"Statins"
|
|
263
|
-
]
|
|
264
|
-
]
|
|
265
|
-
}
|
|
266
|
-
],
|
|
267
|
-
RefId: "E1|Placebo Q2W",
|
|
268
|
-
OriginalName: "Placebo Q2W"
|
|
269
|
-
},
|
|
270
|
-
{
|
|
271
|
-
Id: "Ls",
|
|
272
|
-
RefId: "B1|O1~Placebo Q2W With Concomitant Statin",
|
|
273
|
-
OriginalName: "Placebo Q2W With Concomitant Statin",
|
|
274
|
-
N: 157,
|
|
275
|
-
age: 61.6,
|
|
276
|
-
ageSD: 9.7,
|
|
277
|
-
male: 64.3312101910828,
|
|
278
|
-
Interventions: [
|
|
279
|
-
{
|
|
280
|
-
termIds: [
|
|
281
|
-
[
|
|
282
|
-
"SUGeLS"
|
|
283
|
-
],
|
|
284
|
-
[
|
|
285
|
-
"SUBYEL",
|
|
286
|
-
"SUB_Oc"
|
|
287
|
-
]
|
|
288
|
-
]
|
|
289
|
-
}
|
|
290
|
-
]
|
|
291
|
-
}
|
|
292
|
-
];
|
|
293
|
-
var hasDocData = true;
|
|
294
|
-
var hasRapidExtract = false;
|
|
295
|
-
var N = 803;
|
|
296
|
-
var queryScore = 1.4868329805051381;
|
|
297
|
-
var matchingScore = 7.960635921410255;
|
|
298
|
-
var score = 22.084654254966498;
|
|
299
|
-
var outcomes = [
|
|
300
|
-
{
|
|
301
|
-
id: "179246387",
|
|
302
|
-
type: "Change",
|
|
303
|
-
unit: "%",
|
|
304
|
-
termIds: [
|
|
305
|
-
[
|
|
306
|
-
"SUF0R",
|
|
307
|
-
"SUBskP"
|
|
308
|
-
]
|
|
309
|
-
],
|
|
310
|
-
quantifiers: [
|
|
311
|
-
],
|
|
312
|
-
name: "Calculated LDL-C in Not Receiving Concomitant Statin Therapy - On-Treatment Analysis",
|
|
313
|
-
cells: [
|
|
314
|
-
{
|
|
315
|
-
number: -0.4,
|
|
316
|
-
unit: "%",
|
|
317
|
-
group: "3!",
|
|
318
|
-
varType: "se",
|
|
319
|
-
N: 70,
|
|
320
|
-
se: 2,
|
|
321
|
-
sd: 16.73
|
|
322
|
-
},
|
|
323
|
-
{
|
|
324
|
-
number: -54.6,
|
|
325
|
-
unit: "%",
|
|
326
|
-
group: "4r",
|
|
327
|
-
varType: "se",
|
|
328
|
-
N: 37,
|
|
329
|
-
se: 2.8,
|
|
330
|
-
sd: 17.03
|
|
331
|
-
},
|
|
332
|
-
{
|
|
333
|
-
number: -59.4,
|
|
334
|
-
unit: "%",
|
|
335
|
-
group: "zB",
|
|
336
|
-
varType: "se",
|
|
337
|
-
N: 141,
|
|
338
|
-
se: 1.4,
|
|
339
|
-
sd: 16.62
|
|
340
|
-
}
|
|
341
|
-
],
|
|
342
|
-
time: {
|
|
343
|
-
Id: 67122072,
|
|
344
|
-
Low: {
|
|
345
|
-
Value: "Baseline"
|
|
346
|
-
},
|
|
347
|
-
High: {
|
|
348
|
-
"Number": 24,
|
|
349
|
-
Unit: "wk"
|
|
350
|
-
},
|
|
351
|
-
Type: "Total",
|
|
352
|
-
days: 168,
|
|
353
|
-
description: "24wk"
|
|
354
|
-
},
|
|
355
|
-
score: 2.08,
|
|
356
|
-
matchingTerm: "SUF0R",
|
|
357
|
-
suggestedPositive: false,
|
|
358
|
-
sourceUnit: "%"
|
|
359
|
-
},
|
|
360
|
-
{
|
|
361
|
-
id: "179246389",
|
|
362
|
-
type: "Change",
|
|
363
|
-
unit: "%",
|
|
364
|
-
termIds: [
|
|
365
|
-
[
|
|
366
|
-
"SUF0R",
|
|
367
|
-
"SUBskP"
|
|
368
|
-
]
|
|
369
|
-
],
|
|
370
|
-
quantifiers: [
|
|
371
|
-
],
|
|
372
|
-
name: "Calculated LDL-C in Receiving Concomitant Statin Therapy - On-Treatment Analysis",
|
|
373
|
-
cells: [
|
|
374
|
-
{
|
|
375
|
-
number: -0.3,
|
|
376
|
-
unit: "%",
|
|
377
|
-
group: "Ls",
|
|
378
|
-
varType: "se",
|
|
379
|
-
N: 151,
|
|
380
|
-
se: 2.1,
|
|
381
|
-
sd: 25.81
|
|
382
|
-
},
|
|
383
|
-
{
|
|
384
|
-
number: -55.1,
|
|
385
|
-
unit: "%",
|
|
386
|
-
group: "4E",
|
|
387
|
-
varType: "se",
|
|
388
|
-
N: 75,
|
|
389
|
-
se: 3,
|
|
390
|
-
sd: 25.98
|
|
391
|
-
},
|
|
392
|
-
{
|
|
393
|
-
number: -62.3,
|
|
394
|
-
unit: "%",
|
|
395
|
-
group: "jt",
|
|
396
|
-
varType: "se",
|
|
397
|
-
N: 302,
|
|
398
|
-
se: 1.5,
|
|
399
|
-
sd: 26.07
|
|
400
|
-
}
|
|
401
|
-
],
|
|
402
|
-
time: {
|
|
403
|
-
Id: 67122072,
|
|
404
|
-
Low: {
|
|
405
|
-
Value: "Baseline"
|
|
406
|
-
},
|
|
407
|
-
High: {
|
|
408
|
-
"Number": 24,
|
|
409
|
-
Unit: "wk"
|
|
410
|
-
},
|
|
411
|
-
Type: "Total",
|
|
412
|
-
days: 168,
|
|
413
|
-
description: "24wk"
|
|
414
|
-
},
|
|
415
|
-
score: 2.08,
|
|
416
|
-
matchingTerm: "SUF0R",
|
|
417
|
-
suggestedPositive: false,
|
|
418
|
-
sourceUnit: "%"
|
|
419
|
-
},
|
|
420
|
-
{
|
|
421
|
-
id: "179246393",
|
|
422
|
-
type: "Change",
|
|
423
|
-
unit: "%",
|
|
424
|
-
termIds: [
|
|
425
|
-
[
|
|
426
|
-
"SUF0R",
|
|
427
|
-
"SUBskP"
|
|
428
|
-
]
|
|
429
|
-
],
|
|
430
|
-
quantifiers: [
|
|
431
|
-
],
|
|
432
|
-
name: "Calculated LDL-C in Not Receiving Concomitant Statin Therapy - On-Treatment Analysis",
|
|
433
|
-
cells: [
|
|
434
|
-
{
|
|
435
|
-
number: -0.5,
|
|
436
|
-
unit: "%",
|
|
437
|
-
group: "3!",
|
|
438
|
-
varType: "se",
|
|
439
|
-
N: 70,
|
|
440
|
-
se: 2,
|
|
441
|
-
sd: 16.73
|
|
442
|
-
},
|
|
443
|
-
{
|
|
444
|
-
number: -53.9,
|
|
445
|
-
unit: "%",
|
|
446
|
-
group: "4r",
|
|
447
|
-
varType: "se",
|
|
448
|
-
N: 37,
|
|
449
|
-
se: 2.7,
|
|
450
|
-
sd: 16.42
|
|
451
|
-
},
|
|
452
|
-
{
|
|
453
|
-
number: -60,
|
|
454
|
-
unit: "%",
|
|
455
|
-
group: "zB",
|
|
456
|
-
varType: "se",
|
|
457
|
-
N: 141,
|
|
458
|
-
se: 1.4,
|
|
459
|
-
sd: 16.62
|
|
460
|
-
}
|
|
461
|
-
],
|
|
462
|
-
time: {
|
|
463
|
-
Id: 67122069,
|
|
464
|
-
Low: {
|
|
465
|
-
Value: "Baseline"
|
|
466
|
-
},
|
|
467
|
-
High: {
|
|
468
|
-
"Number": 12,
|
|
469
|
-
Unit: "wk"
|
|
470
|
-
},
|
|
471
|
-
Type: "Total",
|
|
472
|
-
days: 84,
|
|
473
|
-
description: "12wk"
|
|
474
|
-
},
|
|
475
|
-
score: 2.08,
|
|
476
|
-
matchingTerm: "SUF0R",
|
|
477
|
-
suggestedPositive: false,
|
|
478
|
-
sourceUnit: "%"
|
|
479
|
-
},
|
|
480
|
-
{
|
|
481
|
-
id: "179246394",
|
|
482
|
-
type: "Change",
|
|
483
|
-
unit: "%",
|
|
484
|
-
termIds: [
|
|
485
|
-
[
|
|
486
|
-
"SUF0R",
|
|
487
|
-
"SUBskP"
|
|
488
|
-
]
|
|
489
|
-
],
|
|
490
|
-
quantifiers: [
|
|
491
|
-
],
|
|
492
|
-
name: "Calculated LDL-C in Receiving Concomitant Statin Therapy - On-Treatment Analysis",
|
|
493
|
-
cells: [
|
|
494
|
-
{
|
|
495
|
-
number: 1.4,
|
|
496
|
-
unit: "%",
|
|
497
|
-
group: "Ls",
|
|
498
|
-
varType: "se",
|
|
499
|
-
N: 151,
|
|
500
|
-
se: 1.9,
|
|
501
|
-
sd: 23.35
|
|
502
|
-
},
|
|
503
|
-
{
|
|
504
|
-
number: -47.3,
|
|
505
|
-
unit: "%",
|
|
506
|
-
group: "4E",
|
|
507
|
-
varType: "se",
|
|
508
|
-
N: 75,
|
|
509
|
-
se: 2.8,
|
|
510
|
-
sd: 24.25
|
|
511
|
-
},
|
|
512
|
-
{
|
|
513
|
-
number: -58,
|
|
514
|
-
unit: "%",
|
|
515
|
-
group: "jt",
|
|
516
|
-
varType: "se",
|
|
517
|
-
N: 302,
|
|
518
|
-
se: 1.4,
|
|
519
|
-
sd: 24.33
|
|
520
|
-
}
|
|
521
|
-
],
|
|
522
|
-
time: {
|
|
523
|
-
Id: 67122069,
|
|
524
|
-
Low: {
|
|
525
|
-
Value: "Baseline"
|
|
526
|
-
},
|
|
527
|
-
High: {
|
|
528
|
-
"Number": 12,
|
|
529
|
-
Unit: "wk"
|
|
530
|
-
},
|
|
531
|
-
Type: "Total",
|
|
532
|
-
days: 84,
|
|
533
|
-
description: "12wk"
|
|
534
|
-
},
|
|
535
|
-
score: 2.08,
|
|
536
|
-
matchingTerm: "SUF0R",
|
|
537
|
-
suggestedPositive: false,
|
|
538
|
-
sourceUnit: "%"
|
|
539
|
-
}
|
|
540
|
-
];
|
|
541
|
-
var characteristics = [
|
|
542
|
-
{
|
|
543
|
-
id: "179246354",
|
|
544
|
-
type: "Binary",
|
|
545
|
-
isCharacteristic: true,
|
|
546
|
-
termIds: [
|
|
547
|
-
[
|
|
548
|
-
"SUE_c",
|
|
549
|
-
"SUCbN",
|
|
550
|
-
"SUyJj"
|
|
551
|
-
]
|
|
552
|
-
],
|
|
553
|
-
quantifiers: [
|
|
554
|
-
],
|
|
555
|
-
name: "Patients not having adequate control of their hypercholesterolemia based on their individual level of CVD risk",
|
|
556
|
-
cells: [
|
|
557
|
-
],
|
|
558
|
-
number: 100
|
|
559
|
-
}
|
|
560
|
-
];
|
|
561
|
-
var outcomesScore = 18.97947630112307;
|
|
562
|
-
var sampleData = {
|
|
563
|
-
metadata: metadata,
|
|
564
|
-
design: design,
|
|
565
|
-
conditions: conditions,
|
|
566
|
-
phase: phase,
|
|
567
|
-
name: name,
|
|
568
|
-
trialIds: trialIds,
|
|
569
|
-
acronyms: acronyms,
|
|
570
|
-
outcomeCount: outcomeCount,
|
|
571
|
-
id: id,
|
|
572
|
-
groups: groups,
|
|
573
|
-
hasDocData: hasDocData,
|
|
574
|
-
hasRapidExtract: hasRapidExtract,
|
|
575
|
-
N: N,
|
|
576
|
-
queryScore: queryScore,
|
|
577
|
-
matchingScore: matchingScore,
|
|
578
|
-
score: score,
|
|
579
|
-
outcomes: outcomes,
|
|
580
|
-
characteristics: characteristics,
|
|
581
|
-
outcomesScore: outcomesScore
|
|
582
|
-
};
|
|
583
|
-
|
|
6
|
+
const sampleData = JSON.parse(fs.readFileSync(new URL('./example4.json', (document.currentScript && document.currentScript.src || new URL('test.js', document.baseURI).href))));
|
|
7
|
+
|
|
584
8
|
const senmlData = [
|
|
585
9
|
{ bn: '/3303/0/5700', bt: 1278887, v: 35.5 },
|
|
586
10
|
{ t: 10, v: 34 },
|
|
@@ -1264,4 +688,4 @@
|
|
|
1264
688
|
});
|
|
1265
689
|
});
|
|
1266
690
|
|
|
1267
|
-
}(CBOR, chai));
|
|
691
|
+
}(CBOR, chai, fs));
|
package/index.d.ts
CHANGED
|
@@ -1,5 +1,6 @@
|
|
|
1
|
-
|
|
2
|
-
export {
|
|
1
|
+
import { Options } from './decode'
|
|
2
|
+
export { Decoder, decode, addExtension, FLOAT32_OPTIONS, clearSource, roundFloat32, isNativeAccelerationEnabled } from './decode'
|
|
3
|
+
export { Encoder, encode } from './encode'
|
|
3
4
|
import { Transform, Readable } from 'stream'
|
|
4
5
|
|
|
5
6
|
export as namespace CBOR;
|
package/node-index.js
CHANGED
|
@@ -7,16 +7,18 @@ export const mapsAsObjects = true
|
|
|
7
7
|
import { setExtractor } from './decode.js'
|
|
8
8
|
import { createRequire } from 'module'
|
|
9
9
|
|
|
10
|
-
const
|
|
11
|
-
if (extractor)
|
|
12
|
-
setExtractor(extractor.extractStrings)
|
|
10
|
+
const nativeAccelerationDisabled = process.env.CBOR_NATIVE_ACCELERATION_DISABLED !== undefined && process.env.CBOR_NATIVE_ACCELERATION_DISABLED.toLowerCase() === 'true';
|
|
13
11
|
|
|
14
|
-
|
|
12
|
+
if (!nativeAccelerationDisabled) {
|
|
13
|
+
let extractor
|
|
15
14
|
try {
|
|
16
|
-
|
|
17
|
-
|
|
15
|
+
if (typeof require == 'function')
|
|
16
|
+
extractor = require('cbor-extract')
|
|
17
|
+
else
|
|
18
|
+
extractor = createRequire(import.meta.url)('cbor-extract')
|
|
19
|
+
if (extractor)
|
|
20
|
+
setExtractor(extractor.extractStrings)
|
|
18
21
|
} catch (error) {
|
|
19
|
-
|
|
20
|
-
console.warn('For browser usage, directly use cbor-x/decode or cbor-x/encode modules. ' + error.message.split('\n')[0])
|
|
22
|
+
// native module is optional
|
|
21
23
|
}
|
|
22
24
|
}
|
package/package.json
CHANGED
|
@@ -1,7 +1,7 @@
|
|
|
1
1
|
{
|
|
2
2
|
"name": "cbor-x",
|
|
3
3
|
"author": "Kris Zyp",
|
|
4
|
-
"version": "1.2
|
|
4
|
+
"version": "1.3.2",
|
|
5
5
|
"description": "Ultra-fast and conformant CBOR (RFC 8949) implementation with support for numerous tag extensions including records and structured cloning",
|
|
6
6
|
"license": "MIT",
|
|
7
7
|
"types": "./index.d.ts",
|
|
@@ -59,7 +59,7 @@
|
|
|
59
59
|
"/*.ts"
|
|
60
60
|
],
|
|
61
61
|
"optionalDependencies": {
|
|
62
|
-
"cbor-extract": "^
|
|
62
|
+
"cbor-extract": "^2.0.2"
|
|
63
63
|
},
|
|
64
64
|
"devDependencies": {
|
|
65
65
|
"@rollup/plugin-json": "^4.1.0",
|
|
@@ -72,8 +72,5 @@
|
|
|
72
72
|
"mocha": "^8.1.3",
|
|
73
73
|
"rollup": "^1.20.3",
|
|
74
74
|
"rollup-plugin-babel-minify": "^9.0.0"
|
|
75
|
-
},
|
|
76
|
-
"dependencies": {
|
|
77
|
-
"esbuild": "^0.13.15"
|
|
78
75
|
}
|
|
79
76
|
}
|